AG
GOSS icon

Aperio Group’s Gossamer Bio GOSS Stock Holding History

Aperio Group’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-16,519
Closed -$205K – 2439
2020
Q3 		$205K Buy
16,519
+1,702
+11% +$22.6K ﹤0.01% 2221
2020
Q2 		$193K Buy
14,817
+1,226
+9% +$15.4K ﹤0.01% 2186
2020
Q1 		$138K Buy
+13,591
New +$177K ﹤0.01% 2165

Other funds holding GOSS

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Aperio Group's GOSS Position: Q4 2020 in Review

Aperio Group sold out of Gossamer Bio (GOSS) in Q4 2020, closing a stake of 16,519 shares — an estimated $205K sold.

Aperio Group first reported a position in GOSS in Q1 2020 and held it in 3 quarters. The position peaked at $205K in Q3 2020. 122 funds tracked by Wall St. Rank hold GOSS as of Q4 2020.

  • Aperio Group reported no remaining Gossamer Bio position as of Q4 2020 after selling out during the quarter.
  • Aperio Group sold 16,519 Gossamer Bio shares in Q4 2020, an estimated $205K.
  • Aperio Group first reported a position in Gossamer Bio in Q1 2020 and held it in 3 quarters.
  • Aperio Group's Gossamer Bio position peaked at $205K in Q3 2020.
  • 122 funds tracked by Wall St. Rank held Gossamer Bio as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.